A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Inclusion Criteria

• •1. Willing and able to give informed consent, as documented by signed ICF
• •2. Age ≥ 18 years
• •3. Patients with histologically confirmed R/R lymphoma:
• •• Phase IIa （dose escalation study）: patients with relapsed or refractory lymphoma who have failed standard treatment and have no standard treatment options
• •• Phase IIb（ expansion Study ）: Cohort 1 (DLBCL, FL 3b) Histologically confirmed DLBCL, FL 3b (including primary mediastinal B-cell lymphoma) with relapsed/refractory disease
• •Cohort 2 (FL) patients with histologically confirmed R/R FL (Grade 1, 2, 3a)
• •Cohort 3 (MCL): Patients with R/R MCL who had prior therapies
• •Cohort 4 (PTCL): Patients with histologically confirmed R/R PTCL who have failed or cannot tolerate standard therapy
• •4. Patients must have at least one measurable lesion
• •5. Life expectancy ≥ 12 weeks
• •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •7. Adequate bone marrow function, renal function and hepatic function:
• •8. Currently human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or cytomegalovirus (CMV) is inactive
• •9. Female patients of childbearing potential must agree to use a double contraception method and male patients with partners of childbearing potential must also use an effective double contraception method during the study period and for 3 months after the final dose